Mechanisms for Behavior Change and Adherence to Treatment for Comorbid Depression in CKD

Background: Major depressive disorder (MDD) disproportionately affects people with chronic kidney disease (CKD) and is associated with non-adherence. We evaluated facilitators of and barriers to adherence to treatments for MDD among people with CKD. Methods: The CONCORD randomized controlled trial evaluated two treatment strategies vs. control for MDD in people with CKD G3b-5: Behavioral Activation Therapy (BAT) (plus placebo) or antidepressant bupropion (plus clinical management control) administered for 8 weeks, with escalation to a combination of BAT plus bupropion for another 8 weeks in those without MDD remission. The control arm received placebo and clinical management. BAT and clinical management were administered via video-teleconferencing. Focus groups were held virtually among study completers and one-on-one interviews among non-completers. The blinded allocation was kept concealed. An applied thematic analysis approach was used for data analysis using NVivo 15. Results: Fourteen focus groups (total N=52) and seven one-on-one interviews were conducted. The cohort was 58% women, 29% Black persons, and 31% Hispanic persons. Median (IQR) age was 59 (51, 64) years and mean (SD) estimated glomerular filtration rate was 27 (9) mL/min/1.73 m 2 . Adherence to study capsule by pill count was higher among focus group vs. one-on-one participants, but adherence to video-teleconferencing sessions was similar. Barriers to drug adherence included polypharmacy, large pill size, side effects attributed to study capsule, and forgetting to take medication. Facilitators of adherence included expectation of symptom improvement and desire to help others by knowledge gained. Participants reported a positive impact of participation on overall functioning and symptoms and indicated that skills learned in teletherapy were helpful. Some perceived video-teleconferencing sessions as more effective than medication, others attributed benefit to a combination of medication and video-teleconferencing, and a minority perceived medication as most effective. Conclusion: Facilitators of and barriers to treatment adherence can inform the management of MDD in people with CKD.

Authors

Institutions

Publication Details

Journal
Clinical Journal of the American Society of Nephrology
Published
2026-11-19
DOI
https://doi.org/10.2215/cjn.0000001267
Primary Topic
Medication Adherence and Compliance
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mechanisms for Behavior Change and Adherence to Treatment for Comorbid Depression in CKD

Xiaoyue Zhang, Lynnel C. Goodman, Rajnish Mehrotra, Genna Hymowitz et al.
Clinical Journal of the American Society of Nephrology
Medication Adherence and Compliance
article

Mechanisms for Behavior Change and Adherence to Treatment for Comorbid Depression in CKD

Xiaoyue Zhang, Lynnel C. Goodman, Rajnish Mehrotra, Genna Hymowitz, L. Parker Gregg, Amelia N. Dubovsky, S. Susan Hedayati, Meredith C. McAdams, Madhukar H. Trivedi, Thomas Carmody, Giselle A. Gerardi
article en

Abstract

Background: Major depressive disorder (MDD) disproportionately affects people with chronic kidney disease (CKD) and is associated with non-adherence. We evaluated facilitators of and barriers to adherence to treatments for MDD among people with CKD. Methods: The CONCORD randomized controlled trial evaluated two treatment strategies vs. control for MDD in people with CKD G3b-5: Behavioral Activation Therapy (BAT) (plus placebo) or antidepressant bupropion (plus clinical management control) administered for 8 weeks, with escalation to a combination of BAT plus bupropion for another 8 weeks in those without MDD remission. The control arm received placebo and clinical management. BAT and clinical management were administered via video-teleconferencing. Focus groups were held virtually among study completers and one-on-one interviews among non-completers. The blinded allocation was kept concealed. An applied thematic analysis approach was used for data analysis using NVivo 15. Results: Fourteen focus groups (total N=52) and seven one-on-one interviews were conducted. The cohort was 58% women, 29% Black persons, and 31% Hispanic persons. Median (IQR) age was 59 (51, 64) years and mean (SD) estimated glomerular filtration rate was 27 (9) mL/min/1.73 m 2 . Adherence to study capsule by pill count was higher among focus group vs. one-on-one participants, but adherence to video-teleconferencing sessions was similar. Barriers to drug adherence included polypharmacy, large pill size, side effects attributed to study capsule, and forgetting to take medication. Facilitators of adherence included expectation of symptom improvement and desire to help others by knowledge gained. Participants reported a positive impact of participation on overall functioning and symptoms and indicated that skills learned in teletherapy were helpful. Some perceived video-teleconferencing sessions as more effective than medication, others attributed benefit to a combination of medication and video-teleconferencing, and a minority perceived medication as most effective. Conclusion: Facilitators of and barriers to treatment adherence can inform the management of MDD in people with CKD.

Clinical Journal of the American Society of Nephrology
Michael E. DeBakey VA Medical Center (US), Baylor College of Medicine (US), University of Washington (US), Stony Brook School (US), Health Services Research & Development (US), Stony Brook Medicine (US), VA North Texas Health Care System (US), Center for Innovation (US), Stony Brook University (US), The University of Texas Southwestern Medical Center (US)
Medication Adherence and Compliance
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon